NOVAVAX INC (NVAX) Spending and interest coverage
- R&D / revenue · 12 months: Value 82.24%; Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 7.81%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value (m); Formula and calculation Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | 82.24% | Research and development expense / revenue. Period ending 2026-06-30. $340.31M ÷ $413.80M × 100 ≈ 82.24% |
| Stock-based compensation / revenue · 12 months | 7.81% | Share-based compensation / revenue. Period ending 2026-06-30. $32.33M ÷ $413.80M × 100 ≈ 7.81% |
| Interest coverage · 12 months | (m) | Estimated: average term debt × dated USD coupon proxy + average commercial paper × matching-currency disclosed rate at or before period end. Swaps, foreign-exchange, lease interest and amortization are not quantified. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | 340.31M USD | Research and Development Expense |
| Revenue | 413.80M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Stock-based compensation | 32.33M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | -234.13M USD | Operating Income (Loss) |
| Interest expense · reported / estimated | (m) | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: (m). Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $340.31M | $413.80M | $32.33M | $-234.13M | (m) | 82.24% | 7.81% | (m) | (m) |
| 2026-03-31 | $348.86M | $596.34M | $33.45M | $-78.15M | (m) | 58.50% | 5.61% | (m) | (m) |
| 2025-12-31 | $342.32M | $1.12B | $36.02M | $452.80M | (m) | 30.47% | 3.21% | (m) | (m) |
| 2025-09-30 | $370.82M | $1.06B | $38.50M | $307.49M | (m) | 34.83% | 3.62% | (m) | (m) |
| 2025-06-30 | $359.71M | $1.08B | $42.00M | $351.49M | (m) | 33.35% | 3.89% | (m) | (m) |
| 2025-03-31 | $387.43M | $1.25B | $46.88M | $411.41M | (m) | 30.88% | 3.74% | (m) | (m) |
| 2024-12-31 | $391.17M | $682.16M | $48.15M | $-248.93M | (m) | 57.34% | 7.06% | (m) | (m) |
| 2024-09-30 | $451.49M | $885.19M | $53.36M | $-301.42M | (m) | 51.00% | 6.03% | (m) | (m) |
| 2024-06-30 | $470.55M | $987.67M | $62.07M | $-293.03M | (m) | 47.64% | 6.28% | (m) | (m) |
| 2024-03-31 | $583.08M | $996.61M | $68.27M | $-398.57M | $14.21M | 58.51% | 6.85% | -28.05× | Reported |
| 2023-12-31 | $737.50M | $983.71M | $85.36M | $-566.51M | $14.42M | 74.97% | 8.68% | -39.30× | Reported |
| 2023-09-30 | $830.65M | $1.05B | $97.47M | $-626.82M | $14.90M | 79.13% | 9.29% | -42.07× | Reported |
| 2023-06-30 | $1.03B | $1.60B | $108.26M | $-628.38M | $16.21M | 64.40% | 6.78% | -38.76× | Reported |
| 2023-03-31 | $1.10B | $1.36B | $126.01M | $-1.17B | $19.32M | 80.87% | 9.27% | -60.39× | Reported |
| 2022-12-31 | $1.24B | $1.98B | $130.30M | $-644.74M | $19.88M | 62.33% | 6.57% | -32.43× | Reported |
| 2022-09-30 | $1.94B | $1.85B | $134.69M | $-1.23B | $20.42M | 105.07% | 7.29% | -60.04× | Reported |
| 2022-06-30 | $2.04B | $1.29B | $148.42M | $-1.41B | $21.43M | 158.36% | 11.50% | -65.60× | Reported |
| 2022-03-31 | $2.33B | $1.40B | $163.50M | $-1.27B | $21.16M | 165.74% | 11.65% | -59.94× | Reported |
| 2021-12-31 | $2.53B | $1.15B | $183.63M | $-1.69B | $21.13M | 221.11% | 16.02% | -79.83× | Reported |
| 2021-09-30 | $1.97B | $1.20B | $201.89M | $-1.04B | $19.87M | 163.88% | 16.77% | -52.57× | Reported |
| 2021-06-30 | $1.86B | $1.18B | $222.32M | $-931.26M | $19.15M | 157.25% | 18.81% | -48.64× | Reported |
| 2021-03-31 | $1.32B | $919.45M | $177.13M | $-602.45M | $16.58M | 143.87% | 19.26% | -36.33× | Reported |
| 2020-12-31 | $747.03M | $475.60M | $128.03M | $-416.72M | $15.14M | 157.07% | 26.92% | -27.52× | Reported |
| 2020-09-30 | $375.17M | $204.75M | $81.85M | $-262.57M | $14.67M | 183.23% | 39.97% | -17.90× | Reported |
| 2020-06-30 | $99.69M | $50.24M | $18.77M | $-83.62M | $13.61M | 198.44% | 37.35% | -6.14× | Reported |
| 2020-03-31 | $95.26M | $18.06M | $15.46M | $-103.25M | $13.61M | 527.57% | 85.59% | -7.59× | Reported |
| 2019-12-31 | $113.84M | $18.66M | $17.05M | $-120.58M | $13.61M | 610.02% | 91.35% | -8.86× | Reported |
| 2019-09-30 | $127.92M | $15.97M | $17.19M | $-138.39M | $13.61M | 800.83% | 107.61% | -10.17× | Reported |
| 2019-06-30 | $150.63M | $21.20M | $19.00M | $-165.30M | $13.61M | 710.49% | 89.60% | -12.14× | Reported |
| 2019-03-31 | $164.76M | $28.62M | $18.63M | $-170.63M | $13.61M | 575.73% | 65.09% | -12.54× | Reported |
| 2018-12-31 | $173.80M | $34.29M | $18.31M | $-173.92M | $13.61M | 506.87% | 53.41% | -12.78× | Reported |
| 2018-09-30 | $180.04M | $38.57M | $20.68M | $-175.19M | $13.73M | 466.75% | 53.61% | -12.76× | Reported |
| 2018-06-30 | $180.57M | $39.19M | $20.58M | $-174.92M | $13.85M | 460.77% | 52.51% | -12.63× | Reported |
| 2018-03-31 | $175.29M | $35.15M | $20.84M | $-174.40M | $13.96M | 498.72% | 59.29% | -12.49× | Reported |
| 2017-12-31 | $168.44M | $31.18M | $19.81M | $-171.71M | $14.07M | 540.27% | 63.54% | -12.20× | Reported |
| 2017-09-30 | $169.88M | $26.16M | $16.84M | $-177.97M | $14.06M | 649.31% | 64.35% | -12.66× | Reported |
| 2017-06-30 | $181.00M | $21.04M | $17.67M | $-199.65M | $14.05M | 860.18% | 83.97% | -14.21× | Reported |
| 2017-03-31 | $206.64M | $16.82M | $18.41M | $-234.68M | $14.05M | 1228.91% | 109.50% | -16.71× | Reported |
| 2016-12-31 | $237.94M | $15.35M | $19.16M | $-269.11M | $12.96M | 1549.79% | 124.80% | -20.76× | Reported |
| 2016-09-30 | $262.74M | $15.81M | $19.53M | $-293.97M | $9.57M | 1662.19% | 123.57% | -30.71× | Reported |
| 2016-06-30 | $240.42M | $19.10M | $19.14M | $-263.86M | $6.13M | 1258.70% | 100.18% | -43.08× | Reported |
| 2016-03-31 | $203.25M | $30.59M | $16.46M | $-208.19M | $2.63M | 664.41% | 53.81% | -79.01× | Reported |
| 2015-12-31 | $162.64M | $36.25M | $13.43M | $-157.24M | $241.00K | 448.67% | 37.05% | -652.43× | Reported |
| 2015-09-30 | $109.18M | $37.12M | $10.79M | $-110.00M | $133.00K | 294.12% | 29.05% | -827.06× | Reported |
| 2015-06-30 | $100.48M | $38.81M | $7.71M | $-96.59M | $116.00K | 258.91% | 19.87% | -832.67× | Reported |
| 2015-03-31 | $90.81M | $33.07M | $6.98M | $-93.62M | $141.00K | 274.55% | 21.11% | -663.96× | Reported |
| 2014-12-31 | $79.44M | $30.66M | $6.09M | $-83.69M | $157.00K | 259.09% | 19.86% | -533.06× | Reported |
| 2014-09-30 | $65.26M | $32.68M | $5.28M | $-66.28M | $178.00K | 199.67% | 16.15% | -372.35× | Reported |
| 2014-06-30 | $59.99M | $29.27M | $4.25M | $-61.77M | $195.00K | 204.94% | 14.52% | -316.76× | Reported |
| 2014-03-31 | $55.57M | $24.54M | $3.04M | $-56.81M | $190.00K | 226.41% | 12.37% | -299.02× | Reported |
| 2013-12-31 | $50.31M | $20.91M | $2.48M | $-52.43M | $160.00K | 240.54% | 11.86% | -327.71× | Reported |
| 2013-09-30 | $42.78M | $16.73M | $2.21M | $-47.68M | $152.00K | 255.66% | 13.19% | -313.66× | Reported |
| 2013-06-30 | $35.48M | $17.70M | $2.04M | $-39.24M | $94.00K | 200.47% | 11.51% | -417.50× | Reported |
| 2013-03-31 | $30.16M | $21.27M | $1.99M | $-32.20M | $51.00K | 141.79% | 9.34% | -631.43× | Reported |
| 2012-12-31 | $26.06M | $22.08M | $2.09M | $-29.66M | $32.00K | 118.05% | 9.47% | -927.03× | Reported |
| 2012-09-30 | $21.06M | (m) | $2.04M | $-24.43M | $15.00K | (m) | (m) | -1628.60× | Reported |
| 2012-06-30 | $18.71M | (m) | $2.09M | $-21.55M | $11.00K | (m) | (m) | -1959.09× | Reported |
| 2012-03-31 | $17.89M | (m) | $2.20M | $-21.62M | $10.00K | (m) | (m) | -2161.60× | Reported |
| 2011-12-31 | $17.89M | (m) | $2.05M | $-21.58M | $9.00K | (m) | (m) | -2397.67× | Reported |
| 2011-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-12-31 | $28.03M | (m) | $1.34M | $-38.49M | $9.00K | (m) | (m) | -4277.11× | Reported |
| 2010-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-12-31 | $25.78M | (m) | $1.53M | $-37.38M | $786.00K | (m) | (m) | -47.56× | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Inhibrx Biosciences, Inc. (INBX) | United States | $1.477B | -10.08 |
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |